Literature DB >> 1824743

Pharmacokinetics, pharmacodynamics, and rational opioid selection.

S L Shafer1, J R Varvel.   

Abstract

Fentanyl, alfentanil, and sufentanil have important pharmacokinetic and pharmacodynamic differences. Selecting one of these opioid analgesics as an adjunct to general anesthesia requires appreciation of the relationship between the pharmacokinetic and pharmacodynamic characteristics of these drugs and the onset of and recovery from drug effect. Using a pharmacokinetic-pharmacodynamic model, the authors simulated the decrease in plasma fentanyl, alfentanil, and sufentanil concentration after intravenous administration by either bolus injection, brief infusion, or prolonged infusion. The percentage change in concentration, rather than absolute concentration, was simulated to permit comparison of the relative opioid concentration independently of drug potency. These computer simulations quantified the relationship between infusion duration and the time required for recovery after termination of the infusion. The analysis suggests that alfentanil is best used for operations longer than 6-8 h when a rapid decrease in effect site (i.e., biophase) opioid concentration is desired after discontinuation of the infusion. Alfentanil may also be the most appropriate drug to provide a transient peak effect after a single bolus. Although sufentanil has longer distribution and elimination half-lives than alfentanil, recovery from sufentanil infusions may be more rapid than recovery from alfentanil infusions for operations shorter than 6-8 h. These computer simulations demonstrate that simply comparing pharmacokinetic parameters (e.g., half-lives) of different drugs will not predict the relative rates of decrease in effect site concentrations after either an intravenous bolus or a continuous infusion.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1824743     DOI: 10.1097/00000542-199101000-00010

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  68 in total

Review 1.  Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans.

Authors:  L J Lesko; M Rowland; C C Peck; T F Blaschke
Journal:  Pharm Res       Date:  2000-11       Impact factor: 4.200

Review 2.  General anaesthesia for supratentorial neurosurgery.

Authors:  P Ravussin; O Wilder-Smith
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

3.  All half-lives are wrong, but some half-lives are useful.

Authors:  J G Wright; A V Boddy
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 4.  Context-sensitive half-times: what are they and how valuable are they in anaesthesiology?

Authors:  James M Bailey
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  [Modern concepts in pharmacokinetics of intravenous anesthetics].

Authors:  T Heidegger; C F Minto; T W Schnider
Journal:  Anaesthesist       Date:  2004-01       Impact factor: 1.041

Review 6.  Pharmacokinetics and pharmacodynamics for the clinician.

Authors:  D R Stanski
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

Review 7.  Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations.

Authors:  Carmen Walter; Claudia Knothe; Jörn Lötsch
Journal:  Clin Pharmacokinet       Date:  2016-07       Impact factor: 6.447

8.  Application of pharmacodynamic modeling for designing time-variant dosing regimens to overcome nitroglycerin tolerance in experimental heart failure.

Authors:  J A Bauer; J P Balthasar; H L Fung
Journal:  Pharm Res       Date:  1997-09       Impact factor: 4.200

Review 9.  Pharmacokinetic optimisation of opioid treatment in acute pain therapy.

Authors:  R N Upton; T J Semple; P E Macintyre
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

10.  Desflurane requirements for laryngeal mask airway insertion during inhalation induction.

Authors:  Hwa-Yong Shin; Jung-Ae Lim; Seong-Hyop Kim; Seung-Woo Baek; Duk-Kyung Kim
Journal:  J Anesth       Date:  2009-05-15       Impact factor: 2.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.